China OKs study of Telix PET radiotracer for kidney cancer

2016 08 23 17 04 30 620 Kidney 400

Telix Pharmaceuticals has received approval in China for a study of its investigational TLX250-CDx radiotracer for PET imaging of renal cancer.

The Chinese National Medical Products Administration Center for Drug Evaluation has approved a pivotal phase-III registration study that will bridge to Telix's phase-III study, Zirconium in Renal Cancer Oncology (ZIRCON) for TLX250-CDx.

TLX250-CDx is being developed as a PET imaging agent to characterize indeterminate renal masses previously identified on CT or MRI as clear cell renal cell cancer (ccRCC) or non-ccRCC.

This ZIRCON study aims to provide supplementary data obtained in a Chinese population with the hopes of establishing that the diagnostic efficacy of this investigational agent is equivalent in Chinese and Western populations. A dosimetry study enrolling 10 patients will precede the multicenter phase-III bridging study, which is expected to enroll 100 patients.

Page 1 of 589
Next Page